Balancing Efficacy and Well-being: PRO Dynamics and Skeletal Safety in the Phase 3 PSMAddition Trial for mHSPC

Balancing Efficacy and Well-being: PRO Dynamics and Skeletal Safety in the Phase 3 PSMAddition Trial for mHSPC

At a recent international oncology symposium, Michael Morris, MD, from Memorial Sloan Kettering Cancer Center (MSKCC), delivered an in-depth academic report on Abstract #18. The presentation focused on the latest data regarding health-related quality of life (HRQoL), pain, and symptomatic skeletal events (SSE) from the Phase 3 PSMAddition study. This trial evaluates the efficacy and safety of 177Lu-PSMA-617 in combination with androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI) for patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). Below is a summary of the core findings.
Neoplasia | Teams Led by Jianxiang Wang and Shaowei Qiu Reveal Prognostic Heterogeneity in FLT3-ITD–Mutated AML: Clonal Origin and 13q UPD as Key Drivers

Neoplasia | Teams Led by Jianxiang Wang and Shaowei Qiu Reveal Prognostic Heterogeneity in FLT3-ITD–Mutated AML: Clonal Origin and 13q UPD as Key Drivers

Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy. Approximately 20–30% of AML patients harbor FLT3 internal tandem duplication (FLT3-ITD) mutations. FLT3-ITD is a major driver mutation in AML and typically arises as a late genetic event during leukemogenesis, often coexisting with mutations in NPM1, DNMT3A, WT1, and others. Although FLT3-ITD is generally associated with poor prognosis, substantial variability in clinical outcomes has been observed among FLT3-ITD–positive patients. Previous studies have largely focused on the molecular characteristics of FLT3-ITD itself, while the impact of its clonal origin on prognosis has been underexplored. Moreover, the key genetic evolutionary mechanisms driving resistance during progression from newly diagnosed disease to relapsed/refractory (R/R) AML remain incompletely understood.
CASH 2026 Professor Erlie Jiang: Four Decades of Continuity and Innovation — The “Tianjin Model” Pioneering a New Era in Hematopoietic Stem Cell Transplantation

CASH 2026 Professor Erlie Jiang: Four Decades of Continuity and Innovation — The “Tianjin Model” Pioneering a New Era in Hematopoietic Stem Cell Transplantation

The “Tianjin Model” of hematopoietic stem cell transplantation (HSCT) is a distinctive transplant system that integrates standardization, precision, and innovation. It has been progressively developed through nearly four decades of continuous exploration and generational knowledge transfer at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (also known as the Tianjin Institute of Hematology).
ESMO Global Perspective | Professor Denis Soulieres: Lessons From the BURAN Trial and the Road Ahead After Immunotherapy Failure in HNSCC

ESMO Global Perspective | Professor Denis Soulieres: Lessons From the BURAN Trial and the Road Ahead After Immunotherapy Failure in HNSCC

The Phase III BURAN trial, presented at the recent ESMO Congress, evaluated the PI3K inhibitor buparlisib plus paclitaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) who had progressed after PD-1/PD-L1 inhibitor therapy. The study failed to demonstrate improvements in progression-free survival (PFS) or overall survival (OS) compared with paclitaxel alone (median PFS: 4.1 months in both arms; median OS: 9.6 vs 9.7 months), despite a higher objective response rate (ORR) with the combination (30.3% vs 20.7%).
CASH 2026 | Professor Zimin Sun: Current Applications, Core Advantages, and Future Prospects of Umbilical Cord Blood Transplantation

CASH 2026 | Professor Zimin Sun: Current Applications, Core Advantages, and Future Prospects of Umbilical Cord Blood Transplantation

As an emerging modality of hematopoietic stem cell transplantation, umbilical cord blood transplantation (UCBT) has demonstrated unique clinical value in the treatment of various hematologic diseases. From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading hematology experts from China and abroad to explore cutting-edge research and national health priorities. During the conference, Professor Zimin Sun from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, shared in-depth insights into the current clinical status, technical advantages, and evolving research landscape of UCBT.
Yixian Breast Cancer Conference 2025 | Professor Chang Gong: Stratified Optimization and Precision Escalation/De-Escalation in HER2-Positive Breast Cancer

Yixian Breast Cancer Conference 2025 | Professor Chang Gong: Stratified Optimization and Precision Escalation/De-Escalation in HER2-Positive Breast Cancer

HER2-positive breast cancer was once associated with aggressive behavior and poor prognosis. However, with the rapid advancement of targeted therapies—particularly antibody–drug conjugates (ADCs)—this subtype has evolved into a highly treatable and potentially curable disease. In 2025, landmark studies across neoadjuvant, adjuvant, and metastatic settings have reshaped treatment paradigms toward greater precision and individualization. During the 2025 Yixian Breast Cancer Conference and CSCO BC South Forum, Oncology Frontier interviewed Professor Chang Gong from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, who summarized the most impactful annual advances in HER2-positive breast cancer treatment.
Professor Lugui Qiu: Upholding Integrity, Driving Innovation—CSCO Myeloma Expert Committee 2025 Work Summary and 2026 Strategic Plan

Professor Lugui Qiu: Upholding Integrity, Driving Innovation—CSCO Myeloma Expert Committee 2025 Work Summary and 2026 Strategic Plan

From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. As a malignant plasma cell disorder predominantly affecting older adults, multiple myeloma (MM) requires continuous advancement in standardized diagnosis, scientific innovation, and patient-centered management, all of which are critical to the high-quality development of hematologic oncology in China.
Professor Xieqiao Yan: Optimizing Post-Failure Treatment Strategies in Renal Cell Carcinoma After Targeted-Immunotherapy—Exploring New Pathways for Later-Line Therapy

Professor Xieqiao Yan: Optimizing Post-Failure Treatment Strategies in Renal Cell Carcinoma After Targeted-Immunotherapy—Exploring New Pathways for Later-Line Therapy

From January 10 to 11, 2026, the Beijing Young Urologic Oncology Physicians Academic Exchange Conference was successfully held in Beijing. The meeting brought together leading experts and young physicians in urologic oncology to discuss cutting-edge scientific advances and key clinical challenges, with the goal of fostering academic innovation and supporting the growth of emerging clinicians.
SABCS 2025 Insight Broadcast丨Professor Junjie Li: Exploring Precision Biomarkers for Neoadjuvant Therapy in HER2-Positive Breast Cancer

SABCS 2025 Insight Broadcast丨Professor Junjie Li: Exploring Precision Biomarkers for Neoadjuvant Therapy in HER2-Positive Breast Cancer

Spotlight on SABCS, insights delivered live. The 48th San Antonio Breast Cancer Symposium (SABCS) was held from December 9 to 12, 2025, in San Antonio, USA, bringing together cutting-edge research findings and clinical insights from across the global breast cancer community. To efficiently convey the highlights of the meeting, this edition of Insight Broadcast invited Professor Junjie Li from Fudan University Shanghai Cancer Center as an on-site expert commentator. Focusing on neoadjuvant therapy for HER2-positive breast cancer, Professor Li provides an in-depth interpretation of the latest research advances on the use of biomarkers such as tumor-infiltrating lymphocytes (TILs) and circulating tumor DNA (ctDNA) to enable more precise patient selection and response prediction, while critically examining their potential, limitations, and future directions from a clinical perspective.
SABCS Hot Commentary:Professor Xiaoyun Mao: A Breakthrough in “Intensified” First-Line Maintenance Therapy for HER2-Positive Metastatic Breast Cancer

SABCS Hot Commentary:Professor Xiaoyun Mao: A Breakthrough in “Intensified” First-Line Maintenance Therapy for HER2-Positive Metastatic Breast Cancer

At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), results were presented from a study titled “HER2CLIMB-05: A Randomized, Double-Blind Phase III Study of Tucatinib versus Placebo in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy for HER2-Positive Metastatic Breast Cancer” (Abstract No. GS1-01). This study explored an intensified strategy for first-line maintenance therapy in patients with HER2-positive metastatic breast cancer (HER2+ MBC). Oncology Frontier invited Professor Xiaoyun Mao from The First Hospital of China Medical University to provide a detailed overview and expert commentary on the study, with the aim of optimizing clinical decision-making.